PATIENTS SOUGHT FOR EVALUATION OF MANY PROMISING NEW TREATMENTS Patients with Parkinson's disease are currently being sought by the Experimental Therapeutics Branch (ETB) of the National Institute of Neurological Disorders and Stroke (NINDS) for many clinical studies at the NIH campus in Bethesda, Maryland. OPC 14117 is a promising new drug that may slow the progression of the difficulties associated with Parkinson's disease. This outpatient trial involves 9 visits over a period of 24 months. All will receive a thorough medical and neurological evaluation. Candidates should have mild to moderate difficulties, be between 18 and 79 years of age, and in good general health. There is no charge to participate, and in some instances compensation and transportation may be provided. We are also seeking patients for other studies: * For patients with motor fluctuations, dyskinesias and/or freezing, we have a study of dextromethorphan, which involves weekly visits to the day hospital for up to 12 weeks. * Postmenopausal females are needed for a study of the effect of estrogen on parkinsonian symptoms and the response to levodopa. This study requires two brief inpatient as well as outpatient visits over a one month period. Healthy, nonsmoking women with no personal or strong family history of breast or uterine cancer are needed. There is no charge to participate in any of the above studies. To apply, please have your neurologist or family doctor mail or fax pertinent medical records (and MRI results, if available) to: Thomas N. Chase, MD NIH/NINDS/ETB Building 10, Room 5C-103 10 CENTER DR MSC 1406 BETHESDA, MD 20892-1406 Fax Number: 301- 496-6609 For additional information, please contact Marge Gillespie, R.N. or Susan Kastris, R.N. at 1-800-362-3479 or 301-496-4604, or e-mail Michael C. Tierney at [log in to unmask]